Previous 10 |
home / stock / mdnaf / mdnaf news
TORONTO , ON and HOUSTON, TX , April 23, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant, Chairman...
TORONTO, ON and HOUSTON, TX / ACCESSWIRE / March 27, 2019 / Medicenna Therapeutics Corp. (''Medicenna'' or the ''Company'') (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company announced today that Dr. Fahar Merchant, Chairman, President and CEO is scheduled to present at this...
Medicenna Therapeutics ( OTCQB:MDNAF ): Q3 EPS of -C$0.07. Press release More news on: Medicenna Therapeutics Corp., Earnings news and commentary, Consumer stocks news, ,
TORONTO and HOUSTON, TX , Feb. 14, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and nine months ended December 31, 2018 . The f...
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55 Canada NewsWire TORONTO and HOUSTON, TX, Feb. 7, 2019 Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients TORONTO and HOUSTON, TX ...
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109 Canada NewsWire TORONTO, Feb. 6, 2019 Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors TORONTO , Feb. 6, 2019 /CNW/ - Medicenna ...
Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more ...
Medicenna to Host Virtual Roadshow Webinar Canada NewsWire TORONTO and HOUSTON, TX, Jan. 25, 2019 January 29 th , 2019 at 2:00 p.m. ET TORONTO and HOUSTON, TX, Jan. 25, 2019 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or the " Company ") (TSX: MDN...
Preliminary Results on MDNA55 and MDNA109 to be Presented at the Immuno-Oncology 360° Conference Canada NewsWire TORONTO and HOUSTON, Jan. 24, 2019 TORONTO and HOUSTON , Jan. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; O...
News, Short Squeeze, Breakout and More Instantly...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL...